AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31526367 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV Exposed Infants testing EIA positive from the 2012-2013 cross-sectional survey
Number of subjects: 580
Study 31526367 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-free survival
Number of subjects: 580
Study 28866864 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 0
Study 28866864 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, race, history of cardiovascular diseases, decreased triglycerides, decreased pulse pressure, and albuminuria
Number of subjects: 0
Study 28866864 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 0
Study 25759400 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg/day, titrated from 30 mg after three days)
Number of subjects: 40
Study 25759400 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched, with sham titration)
Number of subjects: 40
Study 25607563 — intervention group
Group type: EXPERIMENTAL
Intervention: Active colloidal oatmeal moisturizer
Number of subjects: 0
Study 25607563 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 22798265 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (∼10 mg/kg every 4 weeks)
Number of subjects: 317
Study 19797259 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0
Study 17457450 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 429
Study 15057903 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (IFN) 3 million units three times weekly plus full course of ribavirin (RBV) at 800 mg/day (group A; n = 53)
Number of subjects: 107
Study 15057903 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa‐2b (IFN) 3 million units three times weekly plus 16 weeks of placebo followed by RBV (group B; n = 54)
Number of subjects: 107
Study 15057903 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (IFN) plus RBV (group A)
Number of subjects: 107
Study 15057903 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa‐2b (IFN) plus RBV (group B)
Number of subjects: 107
Study 15057903 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (IFN) plus RBV (group A) with zidovudine (AZT)
Number of subjects: 107
Study 15057903 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (IFN) plus RBV (group A) without zidovudine (AZT)
Number of subjects: 107
Study 12101381 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive stenting following thrombolytic therapy
Number of subjects: 118
Study 9523907 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose solution (100% energy carbohydrate)
Number of subjects: 9
Study 9523907 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid emulsion (100% energy fat, 20% Intralipid)
Number of subjects: 9
Study 9523907 — intervention group
Group type: COMPARATOR
Intervention: Non-nutrient control (0.9% saline)
Number of subjects: 9
Study 7897784 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day treatment with trimethoprim/sulfamethoxazole (TMP/SMX) - one tablet twice daily for 3 days followed by 7 days of placebo
Number of subjects: 80
Study 7897784 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day treatment with trimethoprim/sulfamethoxazole (TMP/SMX) - one tablet twice daily for 10 days
Number of subjects: 80
Study 2795416 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaroid photorefractive screening without cycloplegia
Number of subjects: 187
Study 2795416 — intervention group
Group type: COMPARATOR
Intervention: Standard cycloplegic retinoscopy
Number of subjects: 187
Study 683224 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter tip at the third to fourth lumbar segment
Number of subjects: 73
Study 683224 — intervention group
Group type: COMPARATOR
Intervention: Catheter tip at the seventh to eighth thoracic segment
Number of subjects: 73
Study 683224 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of antibiotics through the catheter
Number of subjects: 73
Study 31641074 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC) therapy
Number of subjects: 148
Study 31641074 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 148
Study 31399440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (diabetes prevention program)
Number of subjects: 1163
Study 31399440 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1163
Study 27312537 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient adolescents (those who experienced war trauma but did not manifest symptoms on the SDQ or CRIES)
Number of subjects: 710
Study 27312537 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions designed for war-traumatized youth
Number of subjects: 710
Study 25354241 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated acupuncture manipulations
Number of subjects: 12
Study 25354241 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes of local perfusion
Number of subjects: 12
Study 25354241 — intervention group
Group type: COMPARATOR
Intervention: Insertion-only
Number of subjects: 12
Study 25354241 — intervention group
Group type: COMPARATOR
Intervention: Single-manipulation
Number of subjects: 12
Study 23941163 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 23941163 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical equipoise regarding oral anticoagulation
Number of subjects: 0
Study 23941163 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevance of randomized controlled trial
Number of subjects: 0
Study 22131608 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD women
Number of subjects: 16
Study 22131608 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 16
Study 19455483 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood stabilizers (lithium, carbamazepine, divalproex sodium, topiramate, lamotrigine)
Number of subjects: 0
Study 16939067 — intervention group
Group type: EXPERIMENTAL
Intervention: EC-MPS (720 mg b.i.d.)
Number of subjects: 367
Study 16939067 — intervention group
Group type: EXPERIMENTAL
Intervention: EC-MPS
Number of subjects: 367
Study 16939067 — intervention group
Group type: COMPARATOR
Intervention: MMF
Number of subjects: 367
Study 15208587 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAM33 16-SNP haplotype (frequency, 14.6% in white subjects)
Number of subjects: 652
Study 15208587 — intervention group
Group type: EXPERIMENTAL
Intervention: Two SNPs in strong linkage disequilibrium (T1 and T+1)
Number of subjects: 652
Study 11042570 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by one course of perioperative chemotherapy
Number of subjects: 281
Study 11042570 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 281
Study 9130892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptorelin
Number of subjects: 0
Study 9130892 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated cells)
Number of subjects: 0
Study 8453963 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil 25 mg daily for 1 week
Number of subjects: 12
Study 8453963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3739562 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide (2 to 8 mg per day)
Number of subjects: 10
Study 3739562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29390064 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel or Ticagrelor (randomized antiplatelet treatment)
Number of subjects: 4354
Study 27391868 — intervention group
Group type: EXPERIMENTAL
Intervention: FB (formula supplemented with higher DHA and ARA content)
Number of subjects: 96
Study 27391868 — intervention group
Group type: COMPARATOR
Intervention: FA (standard infant formula)
Number of subjects: 96
Study 27391868 — intervention group
Group type: COMPARATOR
Intervention: Breast milk
Number of subjects: 96
Study 25937522 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus cetuximab
Number of subjects: 118
Study 25937522 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4
Number of subjects: 118
Study 23908302 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (full ablative laser pretreatment)
Number of subjects: 10
Study 23908302 — intervention group
Group type: COMPARATOR
Intervention: Group B (fractional ablative laser pretreatment)
Number of subjects: 10
Study 21039140 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD group
Number of subjects: 67
Study 21039140 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer module (ICM) group
Number of subjects: 67
Study 21039140 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 19430389 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac (1%)
Number of subjects: 50
Study 19430389 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 50
Study 16930256 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus standard monotherapies
Number of subjects: 3455
Study 16930256 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR-adjusted outcomes
Number of subjects: 3455
Study 16930256 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude Day 28 failure rates
Number of subjects: 3455
Study 16930256 — intervention group
Group type: EXPERIMENTAL
Intervention: Unresolved infections counted as failures
Number of subjects: 3455
Study 16930256 — intervention group
Group type: EXPERIMENTAL
Intervention: Unresolved infections excluded from analysis
Number of subjects: 3455
Study 12882668 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 degrees lateral decubital trans-abdominal laparoscopic approach
Number of subjects: 30
Study 12882668 — intervention group
Group type: COMPARATOR
Intervention: 30 degrees decubital laparoscopic operation
Number of subjects: 30
Study 11099655 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-converted group-B-to-group-O (ECO) RBCs
Number of subjects: 24
Study 11099655 — intervention group
Group type: COMPARATOR
Intervention: Control group O RBCs
Number of subjects: 24
Study 11099655 — intervention group
Group type: EXPERIMENTAL
Intervention: ECO RBCs
Number of subjects: 24
Study 9194107 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (15 mg/kg twice daily; maximum dosage 750 mg twice daily)
Number of subjects: 108
Study 9194107 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftazidime plus tobramycin (CAZ/TM) for 14 days
Number of subjects: 108
Study 9194107 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftazidime plus tobramycin (CAZ/TM)
Number of subjects: 108
Study 9194107 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 108
Study 1355971 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg orally every 12h for 13 doses and intravenous placebo every 8h (n = 5)
Number of subjects: 14
Study 1355971 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gentamicin 1.7 mg/kg every 8h for 19 doses and oral placebo every 12h (n = 5)
Number of subjects: 14
Study 1355971 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo every 12h and intravenous placebo every 8h (n = 4)
Number of subjects: 14
Study 3030039 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 1-selective metoprolol (50 mg b.i.d.)
Number of subjects: 12
Study 3030039 — intervention group
Group type: COMPARATOR
Intervention: Non-selective propranolol (40 mg b.i.d.)
Number of subjects: 12
Study 31447126 — intervention group
Group type: EXPERIMENTAL
Intervention: NTHi vaccine
Number of subjects: 145
Study 31447126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 28359688 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic matrix and collagenated heterologous bone graft
Number of subjects: 13
Study 28359688 — intervention group
Group type: COMPARATOR
Intervention: Collagenated heterologous bone graft alone
Number of subjects: 13
Study 26493567 — intervention group
Group type: EXPERIMENTAL
Intervention: CM + CBT (n = 69)
Number of subjects: 116
Study 26493567 — intervention group
Group type: COMPARATOR
Intervention: CBT alone (n = 47)
Number of subjects: 116
Study 23333016 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 × 5 Gy plus 4 Gy boost
Number of subjects: 89
Study 23333016 — intervention group
Group type: EXPERIMENTAL
Intervention: 55.8 Gy in 31 fractions with 5‐FU and leucovorin
Number of subjects: 89
Study 23333016 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients (>69 years)
Number of subjects: 89
Study 23333016 — intervention group
Group type: EXPERIMENTAL
Intervention: Local excision (traditional technique, transanal endoscopic microsurgery, Kraske procedure)
Number of subjects: 89
Study 21942620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal PHT (combined 17β‐estradiol plus norethisterone)
Number of subjects: 112
Study 21942620 — intervention group
Group type: COMPARATOR
Intervention: Oral PHT (combined 17β‐estradiol plus norethisterone)
Number of subjects: 112
Study 21942620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal PHT
Number of subjects: 112
Study 21942620 — intervention group
Group type: COMPARATOR
Intervention: Oral PHT
Number of subjects: 112
Study 21942620 — intervention group
Group type: COMPARATOR
Intervention: Nasal PHT vs Oral PHT
Number of subjects: 112
Study 20031737 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 300
Study 20031737 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 300
Study 17079186 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal tracheal incision (H group)
Number of subjects: 40
Study 17079186 — intervention group
Group type: COMPARATOR
Intervention: Window-type tracheal excision (W group)
Number of subjects: 40
Study 15367480 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led secondary prevention clinics
Number of subjects: 1343
Study 15367480 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1343
Study 11934203 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac sodium
Number of subjects: 30
Study 11934203 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine
Number of subjects: 30
Study 11934203 — intervention group
Group type: COMPARATOR
Intervention: Control (Endosol)
Number of subjects: 30
Study 9524395 — intervention group
Group type: EXPERIMENTAL
Intervention: Three‐part intervention aimed at improving communication with the health unit
Number of subjects: 145
Study 9524395 — intervention group
Group type: COMPARATOR
Intervention: Usual disease reporting system
Number of subjects: 145
Study 8023671 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 28
Study 8023671 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 28
Study 3137096 — intervention group
Group type: EXPERIMENTAL
Intervention: 2500 IU hCG intramuscularly on days 3, 6, and 9 after ovulation induction by 10,000 IU of hCG
Number of subjects: 74
Study 3137096 — intervention group
Group type: COMPARATOR
Intervention: Control group (357 ovulation induction cycles)
Number of subjects: 74
Study 31533663 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsules (Lactobacillus rhamnosus DSM 14870 and Lactobacillus gasseri DSM 14869) self-administered vaginally once daily for 30 days, then once a week until Day 190.
Number of subjects: 39
Study 31533663 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsules self-administered vaginally after antibiotic treatment in Group 2.
Number of subjects: 39
Study 31533663 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple oral antibiotic combination (cefixime 400 mg stat, doxycycline 100 mg BD for 7 days, metronidazole 2 g stat) in Group 2.
Number of subjects: 39
Study 31533663 — intervention group
Group type: COMPARATOR
Intervention: No intervention in Group 3 (control group).
Number of subjects: 39
Study 27449969 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine injection of 1000 IU of hCG before embryo transfer (ET) (n=62)
Number of subjects: 161
Study 27449969 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo group receiving an intrauterine injection of physiological saline before ET (n=49)
Number of subjects: 161
Study 27449969 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intrauterine injection (n=50)
Number of subjects: 161
Study 27449969 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 161
Study 25479412 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise reduction algorithm ClearVoice
Number of subjects: 20
Study 23690846 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga and compassion meditation program (YCMP), 8 weeks
Number of subjects: 46
Study 23690846 — intervention group
Group type: COMPARATOR
Intervention: Control group, untreated, 8 weeks
Number of subjects: 46
Study 19878123 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin analogues (latanoprost, travoprost, bimatoprost)
Number of subjects: 129
Study 19878123 — intervention group
Group type: COMPARATOR
Intervention: β-blockers (control)
Number of subjects: 129
Study 19878123 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 129
Study 19165383 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1,200 mg)
Number of subjects: 670
Study 19165383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 670
Study 16916007 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence based patient manual
Number of subjects: 249
Study 16916007 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet about COPD from the Australian Lung Foundation
Number of subjects: 249
Study 15109321 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-part targeted resident physician educational program (educational presentation, skills workshop, peer comparison feedback)
Number of subjects: 0
Study 15109321 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11502639 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol xinafoate powder, 50 microg bid
Number of subjects: 0
Study 11502639 — intervention group
Group type: COMPARATOR
Intervention: Oral montelukast, 10 mg qd
Number of subjects: 0
Study 9249084 — intervention group
Group type: EXPERIMENTAL
Intervention: AG group (54 g amino acids + 150 g glucose)
Number of subjects: 45
Study 9249084 — intervention group
Group type: EXPERIMENTAL
Intervention: AGG group (AG + 110 g glucose)
Number of subjects: 45
Study 9249084 — intervention group
Group type: EXPERIMENTAL
Intervention: AGF group (AG + 40 g fat)
Number of subjects: 45
Study 9249084 — intervention group
Group type: EXPERIMENTAL
Intervention: AGL group (58 g amino acids + 60 g glycerol)
Number of subjects: 45
Study 9249084 — intervention group
Group type: COMPARATOR
Intervention: G group (200 g glucose)
Number of subjects: 45
Study 8500237 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg daily)
Number of subjects: 804
Study 8500237 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine (300 mg daily) plus Isosorbide dinitrate (160 mg daily)
Number of subjects: 804
Study 8500237 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 804
Study 3067246 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoxetine (600 mg recommended daily dosage, flexible dosing)
Number of subjects: 52
Study 3067246 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (150 mg recommended daily dosage, flexible dosing)
Number of subjects: 52
Study 31844967 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg hesperidin, twice daily for 12 weeks
Number of subjects: 49
Study 31844967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 30106248 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) combined with one-session treatment (OST)
Number of subjects: 35
Study 30106248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) combined with one-session treatment (OST)
Number of subjects: 35
Study 28498186 — intervention group
Group type: EXPERIMENTAL
Intervention: CQI interventions
Number of subjects: 0
Study 28498186 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study 26590813 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 3691
Study 26590813 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 3691
Study 26590813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen or Letrozole
Number of subjects: 3691
Study 22784013 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone 50 mg
Number of subjects: 158
Study 22784013 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 158
Study 21183870 — intervention group
Group type: EXPERIMENTAL
Intervention: IGL-1
Number of subjects: 140
Study 17953719 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 18
Study 17953719 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine
Number of subjects: 18
Study 17953719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16394687 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic group (tympanic temperature at 36.5 degrees C)
Number of subjects: 30
Study 16394687 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic group (tympanic temperature at 34.5 degrees C)
Number of subjects: 30
Study 16394687 — intervention group
Group type: COMPARATOR
Intervention: Both groups at predicted propofol concentration of 3 microg/ml
Number of subjects: 30
Study 16394687 — intervention group
Group type: COMPARATOR
Intervention: Both groups at predicted propofol concentrations of 3 to 7 microg/ml
Number of subjects: 30
Study 15288403 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 146
Study 15288403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 11751731 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF
Number of subjects: 28
Study 9423722 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic exploration
Number of subjects: 39
Study 9423722 — intervention group
Group type: COMPARATOR
Intervention: Open exploration
Number of subjects: 39
Study 8494559 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous exposure to 45-Hz magnetic fields
Number of subjects: 20